List – 44 Drug Patents that are Expiring in 2029
Last week we uncovered the list of drug patents expiring in 2028. But can highfliers like you and I stop at that?
Well, rest your numbing tendons for we’re here with the list of drug patents expiring in 2029. The list includes not just the drug names but also other information like yearly sales, treatment, ingredients, and the disease they cure which could help them (you) easily choose the drug most profitable to develop a generic version.
Without any delay, here is the list of drugs. Thank us later!
The article has a list of drug patents expiring in 2029. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.
Lamictal Odt
Lamotrigine
| Patents | Expiration Date |
|---|---|
| US7919115 | January 4, 2029 |
Dosage: Oral
Company: GlaxoSmithKline
Ingredients: LAMOTRIGINE
Treatment: Epilepsy
Wakix
Pitolisant
| Patents | Expiration Date |
|---|---|
| US8207197 | February 25, 2029 |
Dosage: Oral
Company: Harmony Biosciences Llc
Ingredients: PITOLISANT HYDROCHLORIDE
Treatment: Excessive Daytime Sleepiness
Caplyta
Lumateperone
| Patents | Expiration Date |
|---|---|
| US9586960 | March 12, 2029 |
| USRE48825 | March 12, 2029 |
| US8648077 | December 1, 2029 |
Dosage: Oral
Company: Intra-cellular Therapies Inc
Ingredients: LUMATEPERONE TOSYLATE
Treatment: Schizophrenia And Bipolar Depression
Desyrel
Trazodone
| Patents | Expiration Date |
|---|---|
| US8133893 | March 13, 2029 |
Dosage: Oral
Company: Pragma Pharmaceuticals Llc
Ingredients: TRAZODONE HYDROCHLORIDE
Treatment: Major Depressive Disorder, Anxiety Disorders, and Difficulties With Sleep
Neuraceq
Florbetaben
| Patents | Expiration Date |
|---|---|
| US7807135 | March 18, 2029 |
Dosage: Intravenous
Company: Life Molecular Imaging Ltd
Ingredients: FLORBETABEN F-18
Treatment: Alzheimer’s Disease
Monoferric
Ferric derisomaltose
| Patents | Expiration Date |
|---|---|
| US10414831 | March 25, 2029 |
| US8815301 | August 14, 2029 |
Dosage: Intravenous
Company: Pharmacosmos As
Ingredients: FERRIC DERISOMALTOSE
Treatment: Iron Deficiency Anemia
Gemtesa
Vibegron
| Patents | Expiration Date |
|---|---|
| US8653260 | April 2, 2029 |
| US8247415 | December 1, 2030 |
Dosage: Oral
Company: Urovant Sciences Gmbh
Ingredients: VIBEGRON
Treatment: Overactive Bladder
Kerendia
Finerenone
| Patents | Expiration Date |
|---|---|
| US8436180 | April 12, 2029 |
Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals Inc
Ingredients: FINERENONE
Treatment: Kidney Function
Triferic
Ferric Pyrophosphate Citrate
| Patents | Expiration Date |
|---|---|
| US7816404 | April 17, 2029 |
Dosage: Intravenous
Company: Rockwell Medical Inc
Ingredients: FERRIC PYROPHOSPHATE CITRATE
Treatment: Iron Deficiency Anemia
Cipro
Ciprofloxacine
| Patents | Expiration Date |
|---|---|
| US9603796 | April 21, 2029 |
Dosage: Oral, Intravenous, Topical
Company: Alk-abello Inc
Ingredients: CIPROFLOXACIN
Treatment: Bacterial Infections
Veklury
Remdesivir
| Patents | Expiration Date |
|---|---|
| USRE46762 | April 22, 2029 |
| US8318682 | April 22, 2029 |
| US8008264 | September 6, 2029 |
| US10065958 | September 16, 2031 |
| US9724360 | October 29, 2035 |
| US9949994 | October 29, 2035 |
Dosage: Intravenous
Company: Gilead Sciences Inc
Ingredients: REMDESIVIR
Treatment: Antiviral
Zejula
Niraparib
| Patents | Expiration Date |
|---|---|
| US8436185 | April 24, 2029 |
| US8071623 | March 27, 2031 |
Dosage: Oral
Company: GlaxoSmithKline Llc
Ingredients: NIRAPARIB TOSYLATE
Treatment: Anti-cancer
Zeposia
Ozanimod
| Patents | Expiration Date |
|---|---|
| US8481573 | May 14, 2029 |
| US8796318 | May 14, 2029 |
Dosage: Oral
Company: Celgene International Ii Sarl
Ingredients: OZANIMOD HYDROCHLORIDE
Treatment: Multiple Sclerosis And Ulcerative Colitis
Tauvid
Flortaucipir (18F)
| Patents | Expiration Date |
|---|---|
| US8932557 | May 19, 2029 |
Dosage: Intravenous
Company: Avid Radiopharmaceuticals Inc
Ingredients: FLORTAUCIPIR F-18
Treatment: Radioactive Diagnostic Agent
Opana Er
Oxymorphone
| Patents | Expiration Date |
|---|---|
| US7851482 | July 10, 2029 |
| US8871779 | November 22, 2029 |
Dosage: Oral
Company: Endo Pharmaceuticals Inc
Ingredients: OXYMORPHONE HYDROCHLORIDE
Treatment: Severe Pain
Braftovi
Encorafenib
| Patents | Expiration Date |
|---|---|
| US8946250 | July 23, 2029 |
| US8541575 | February 26, 2030 |
| US9593099 | August 27, 2030 |
| US8501758 | March 4, 2031 |
Dosage: Oral
Company: Array Biopharma Inc
Ingredients: ENCORAFENIB
Treatment: Melanoma
Odomzo
Sonidegib
| Patents | Expiration Date |
|---|---|
| US8178563 | July 24, 2029 |
| US8063043 | September 15, 2029 |
Dosage: Oral
Company: Sun Pharmaceutical Industries Ltd
Ingredients: SONIDEGIB PHOSPHATE
Treatment: Cancer
Zepatier
Elbasvir/Grazoprevir
| Patents | Expiration Date |
|---|---|
| US7973040 | July 24, 2029 |
| US8871759 | May 4, 2031 |
Dosage: Oral
Company: Merck Sharp And Dohme Corp
Ingredients: ELBASVIR; GRAZOPREVIR
Treatment: Hepatitis C
Talzenna
Talazoparib
| Patents | Expiration Date |
|---|---|
| US8420650 | July 27, 2029 |
| US8012976 | October 19, 2029 |
| US10189837 | October 20, 2031 |
| US8735392 | October 20, 2031 |
Dosage: Oral
Company: Pfizer Inc
Ingredients: TALAZOPARIB TOSYLATE
Treatment: Breast Cancer
Evotaz
Atazanavir/Cobicistat
| Patents | Expiration Date |
|---|---|
| US8148374 | September 3, 2029 |
Dosage: Oral
Company: Bristol-Myers Squibb Co
Ingredients: ATAZANAVIR SULFATE; COBICISTAT
Treatment: HIV/AIDS
Piqray
Alpelisib
| Patents | Expiration Date |
|---|---|
| US8476268 | September 10, 2029 |
| US8227462 | September 28, 2030 |
Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: ALPELISIB
Treatment: Breast Cancer
Tykerb
Lapatinib
| Patents | Expiration Date |
|---|---|
| US8821927 | September 18, 2029 |
Dosage: Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: LAPATINIB DITOSYLATE
Treatment: Breast Cancer
Treanda
Bendamustine
| Patents | Expiration Date |
|---|---|
| US8445524 | September 26, 2029 |
Dosage: Intravenous
Company: Cephalon Inc
Ingredients: BENDAMUSTINE HYDROCHLORIDE
Treatment: Chronic Lymphocytic Leukemia, Multiple Myeloma, And Non-Hodgkin’s Lymphoma
Ingrezza
Valbenazine
| Patents | Expiration Date |
|---|---|
| US8039627 | October 6, 2029 |
| US10065952 | October 28, 2036 |
| US10844058 | October 28, 2036 |
| US10851103 | October 28, 2036 |
| US10851104 | October 28, 2036 |
| US10906902 | December 22, 2036 |
| US10919892 | December 22, 2036 |
| US10906903 | December 22, 2036 |
Dosage: Intravenous
Company: Neurocrine Biosciences Inc
Ingredients: VALBENAZINE TOSYLATE
Treatment: Tardive Dyskinesia
Vitrakvi
Larotrectinib
| Patents | Expiration Date |
|---|---|
| US9127013 | October 21, 2029 |
| US8513263 | December 23, 2029 |
| US10172861 | November 16, 2035 |
| US10799505 | August 15, 2036 |
Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals Inc
Ingredients: LAROTRECTINIB SULFATE
Treatment: Cancer
Rezurock
Belumosudil
| Patents | Expiration Date |
|---|---|
| US8357693 | October 30, 2029 |
Dosage: Oral
Company: Kadmon Pharmaceuticals Llc
Ingredients: BELUMOSUDIL MESYLATE
Treatment: Chronic Graft Versus Host Disease
Cotellic
Cobimetinib
| Patents | Expiration Date |
|---|---|
| US7803839 | November 10, 2029 |
| US10478400 | June 29, 2036 |
| US10590102 | June 30, 2036 |
Dosage: Oral
Company: Genentech Inc
Ingredients: COBIMETINIB FUMARATE
Treatment: Anti-cancer
Recarbrio
Imipenem/Cilastatin/Relebactam
| Patents | Expiration Date |
|---|---|
| US8487093 | November 19, 2029 |
Dosage: Intravenous
Company: Merck Sharp And Dohme
Ingredients: CILASTATIN SODIUM; IMIPENEM; RELEBACTAM
Treatment: Urinary Tract And Complicated Intra-abdominal Infections
Belsomra
Suvorexant
| Patents | Expiration Date |
|---|---|
| US7951797 | November 20, 2029 |
Dosage: Oral
Company: Merck Sharp And Dohme
Ingredients: SUVOREXANT
Treatment: Insomnia
Verzenio
Abemaciclib
| Patents | Expiration Date |
|---|---|
| US7855211 | December 15, 2029 |
Dosage: Oral
Company: Eli Lilly And Co
Ingredients: ABEMACICLIB
Treatment: Breast Cancers
Tavneos
Avacopan
| Patents | Expiration Date |
|---|---|
| US8906938 | December 21, 2029 |
| US8445515 | February 3, 2031 |
Dosage: Oral
Company: Chemocentryx Inc
Ingredients: AVACOPAN
Treatment: Anti-neutrophil Cytoplasmic Auto antibody-associated Vasculitis
Ibsrela
Tenapanor
| Patents | Expiration Date |
|---|---|
| US8541448 | December 30, 2029 |
| US8969377 | December 30, 2029 |
Dosage: Oral
Company: Ardelyx Inc
Ingredients: TENAPANOR HYDROCHLORIDE
Treatment: Irritable Bowel Syndrome
Eucrisa
Crisaborole
| Patents | Expiration Date |
|---|---|
| US8039451 | December 29, 2029 |
Dosage: Topical
Company: Anacor Pharmaceuticals Inc
Ingredients: CRISABOROLE
Treatment: Atopic Dermatitis
With the huge growth in the generic drug market, it has become essential for generic companies like yours to keep a tab on the drugs with a soon-to-be-expired label. But that’s not enough, you have to stay ahead of your competitors too. This is where GreyB comes in!
Our pharma team is working on its toes to extract all the drug patents expiring in the next 8 years from now. Want to get your hands on the complete list?
